EMA Consults On Integrating Needs Of Older People Into Drug Development
Executive Summary
The European Medicines Agency has explained how companies developing medicines for older people can better address the needs of this patient population.
You may also be interested in...
EMA Spells Out Dos and Don’ts Of Developing Drugs For Elderly
The European Medicines Agency has outlined various factors that companies should consider when developing medicines for older patients, who are at the highest risk of encountering usability problems when taking medicines.
Policy Prescriptions: User Fees, EMA Worries, PBM Strategies, PRIME Milestones
The US has plenty of new pharma legislation, Europe has plenty of worries about EMA's Brexit move, pharmacy benefit managers give plenty more scrutiny to which products earn a place on formulary. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.
‘Decentralized Clinical Trials 2.0’ On The Horizon
The remarkable shift towards decentralized clinical trials in the last three years is a testament to how this patient-centric approach of doing research has the potential to solve multiple issues such as time, cost and low participation rates. In this first segment of a two-part article, Pink Sheet looks at how innovation in this sector has just begun and we can expect more action ahead.